The authors performed a desensitization procedure to the antileukotriene by gradually increasing dose of montelukast starting from low dose 5 mg to reach maximum of 10 mg over a period of 2 weeks. The montelukast was stopped as she relapsed with skin rashes following rechallenge during the procedure. Studies have shown that small incremental dose of offending drug tends to reduce leukotriene production and downregulate cysteinyl leukotriene receptors. This further decreases histamine and tryptase release from mast cells. [3] Till date, due to lack of any standardized diagnostic test to confirm montelukast hypersensitivity, clinicians rely on the history of duration, frequency, and clinical symptoms after drug intake to confirm the diagnosis of drug-induced AE.
As per Naranjo probability criteria, the temporal association of drug administration and AE was assessed using set questionnaire. [4] Our patient's Naranjo assessment score was 10, which falls into the accepted range for a "certain/definite" relationship to the drug therapy. The appearance of rash after 28 days of introduction of montelukast shows the adverse drug effect to be of delayed hypersensitivity type. Rechallenge with montelukast during desensitization procedure confirmed the certainty of definite association with the above-said drug. Furthermore, the complete resolution of the skin rashes after discontinuing montelukast goes in favor of the montelukast causing AE.
dIscussIon
Montelukast is generally a well-tolerated drug in adults and elderly patients. AEs are comparable to placebo in several clinical trials. The most common AEs observed in these trials were headache, fatigue, pharyngitis, upper respiratory tract infection, gastrointestinal disorders, and rash. [5, 6] Although package insert lists skin bruising as one of the AEs, not much has been mentioned in existing literature. Skin bruising may be related to arachidonic acid metabolites. Montelukast may inhibit platelet aggregation by interfering with platelet-leukocyte interaction, thereby responsible for bruising. [7] Low-dose corticosteroids given along with montelukast unmask an underlying vasculitis leading to bruising. [8] In children, neuropsychiatric AEs have been reported by blocking CysLT1. Blocking of latter leads to vasculitis in the brain. [9] Hepatobiliary and pancreatic dysfunction has been reported in susceptible patients with altered liver/kidney function tests. [10, 11] conclusIon Through the present case report, we emphasize on the need for monitoring and reporting even the mild AEs of montelukast. This would help clinicians to diagnose the cases effectively. Although leukotriene antagonists are believed to be relatively safe and are widely used in asthma and allergic rhinitis, authors hope that the present case disseminates awareness of potential adverse reactions to montelukast.
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